Dasatinib is an oral multi- BCR/ABL and Src family tyrosine kinase inhibitor, which is used to treat patients with chronic myelogenous leukemia (CML) [70–71] or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) [72]. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.